Risk Paradigm Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Risk Paradigm Group’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.62M	Buy	20,509 +2,304	+13%	+$288K	2.23%	15
2025 Q4	$2.22M	Buy	+18,205	New	+$2.09M	2.14%	22
2018 Q4	$195K	Buy	2,717 +451	+20%	+$36.3K	0.47%	44
2018 Q3	$217K	Buy	2,266 +597	+36%	+$57.9K	0.43%	45
2018 Q2	$159K	Hold	1,669	–	–	0.31%	47
2018 Q1	$146K	Buy	1,669 +1,028	+160%	+$93.8K	0.19%	96
2017 Q4	$54.4K	Buy	641 +403	+169%	+$33.8K	0.06%	155
2017 Q3	$20.6K	Buy	+238	New	+$19.1K	0.03%	192

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Risk Paradigm Group's XBI Position: Q1 2026 in Review

Risk Paradigm Group increased its State Street SPDR S&P Biotech ETF (XBI) stake by 13% in Q1 2026, buying an estimated $288K and bringing the position to 20,509 shares worth $2.62M. The position accounts for 2.23% of the portfolio, ranked #15.

Risk Paradigm Group first reported a position in XBI in Q3 2017 and has held it in 8 quarters since. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Risk Paradigm Group held 20,509 shares of State Street SPDR S&P Biotech ETF worth $2.62M as of Q1 2026.
Risk Paradigm Group bought 2,304 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $288K.
State Street SPDR S&P Biotech ETF made up 2.23% of Risk Paradigm Group's portfolio in Q1 2026, its #15 holding.
Risk Paradigm Group first reported a position in State Street SPDR S&P Biotech ETF in Q3 2017 and has held it in 8 quarters since.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Risk Paradigm Group's 13F filing for Q1 2026, filed 14 May 2026.